168 related articles for article (PubMed ID: 11739463)
1. PRL as a novel potent cofactor for platelet aggregation.
Wallaschofski H; Donné M; Eigenthaler M; Hentschel B; Faber R; Stepan H; Koksch M; Lohmann T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5912-9. PubMed ID: 11739463
[TBL] [Abstract][Full Text] [Related]
2. Differences in platelet activation by prolactin and leptin.
Wallaschofski H; Kobsar A; Sokolova O; Siegemund A; Stepan H; Faber R; Eigenthaler M; Lohmann T
Horm Metab Res; 2004 Jul; 36(7):453-7. PubMed ID: 15305227
[TBL] [Abstract][Full Text] [Related]
3. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia.
Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
J Clin Endocrinol Metab; 2001 Apr; 86(4):1562-7. PubMed ID: 11297584
[TBL] [Abstract][Full Text] [Related]
4. Prolactin, prolactin disorders, and dopamine agonists during pregnancy.
Levin G; Rottenstreich A
Hormones (Athens); 2019 Jun; 18(2):137-139. PubMed ID: 30341577
[TBL] [Abstract][Full Text] [Related]
5. Macroprolactinemia revisited: a study on 106 patients.
Vallette-Kasic S; Morange-Ramos I; Selim A; Gunz G; Morange S; Enjalbert A; Martin PM; Jaquet P; Brue T
J Clin Endocrinol Metab; 2002 Feb; 87(2):581-8. PubMed ID: 11836289
[TBL] [Abstract][Full Text] [Related]
6. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study.
Wallaschofski H; Eigenthaler M; Kiefer M; Donné M; Hentschel B; Gertz HJ; Lohmann T
J Clin Psychopharmacol; 2003 Oct; 23(5):479-83. PubMed ID: 14520125
[TBL] [Abstract][Full Text] [Related]
7. [The reaction of the hypophysis to thyroliberin and metoclopramide in women with hyperprolactinemia].
Tkachenko NN; Potin VV; Beskrovnyĭ SV; Nosova LG
Probl Endokrinol (Mosk); 1990; 36(2):35-40. PubMed ID: 2114023
[TBL] [Abstract][Full Text] [Related]
8. High prolactin level.
Piketty ML; Nataf F; Dilouya A; Roux FX
J Neurosurg; 2000 Feb; 92(2):368-9. PubMed ID: 10659034
[No Abstract] [Full Text] [Related]
9. Effects of prolactin on platelet activation and blood clotting.
Wahlberg J; Tillmar L; Ekman B; Lindahl TL; Landberg E
Scand J Clin Lab Invest; 2013 Apr; 73(3):221-8. PubMed ID: 23570413
[TBL] [Abstract][Full Text] [Related]
10. Establishment of reference values for endocrine tests. II: Hyperprolactinemia.
Le Moli R; Endert E; Fliers E; Mulder T; Prummel MF; Romijn JA; Wiersinga WM
Neth J Med; 1999 Aug; 55(2):71-5. PubMed ID: 10474275
[TBL] [Abstract][Full Text] [Related]
11. Increased serum concentration of nerve growth factor in patients with microprolactinoma.
Sigala S; Martocchia A; Missale C; Falaschi P; Spano P
Neuropeptides; 2004 Feb; 38(1):21-4. PubMed ID: 15003712
[TBL] [Abstract][Full Text] [Related]
12. Prolactin gene expression and secretion during pregnancy and lactation in the rat: role of dopamine and vasoactive intestinal peptide.
Escalada J; Cacicedo L; Ortego J; Melian E; Sánchez-Franco F
Endocrinology; 1996 Feb; 137(2):631-7. PubMed ID: 8593812
[TBL] [Abstract][Full Text] [Related]
13. Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas.
Behan LA; O'Sullivan EP; Glynn N; Woods C; Crowley RK; Tun TK; Smith D; Thompson CJ; Agha A
J Endocrinol Invest; 2013; 36(7):508-14. PubMed ID: 23385474
[TBL] [Abstract][Full Text] [Related]
14. Increased thyroid-stimulating hormone response to thyrotropin-releasing hormone in hyperprolactinemic women.
Seki K; Kato K
J Clin Endocrinol Metab; 1985 Dec; 61(6):1138-41. PubMed ID: 3932450
[TBL] [Abstract][Full Text] [Related]
15. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia.
Vilar L; Naves LA; Freitas MC; Lima M; Canadas V; Albuquerque JL; Lyra R; Azevedo MF; Casulari LA
Minerva Endocrinol; 2007 Jun; 32(2):79-86. PubMed ID: 17557033
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of hypothalamic hyperprolactinemia.
Ferrari C; Rampini P; Benco R; Caldara R; Scarduelli C; Crosignani PG
J Clin Endocrinol Metab; 1982 Nov; 55(5):897-901. PubMed ID: 6811605
[TBL] [Abstract][Full Text] [Related]
17. [Effects of therapy and pregnancy on hyperprolactemia caused by a pituitary adenoma. A clinical case].
Pasinetti E; Schivardi MR; Falsetti L; Gastaldi A
Minerva Ginecol; 1989 Mar; 41(3):157-60. PubMed ID: 2666885
[TBL] [Abstract][Full Text] [Related]
18. The characteristics of acromegalic patients with hyperprolactinemia and the differences with hyperprolactinemia patients.
Huan C; Cui G; Ren Z
Pak J Pharm Sci; 2015 Mar; 28(2 Suppl):713-8. PubMed ID: 25796163
[TBL] [Abstract][Full Text] [Related]
19. Effects of pregnancy, delivery and lactation in hyperprolactinemia with prolactin producing pituitary adenoma.
Kondo I; Suganuma N; Kimura T; Matsuzawa K; Osawa M; Masahashi T; Mizutani S; Narita O; Tomoda Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):595-600. PubMed ID: 2754290
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
